Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on September 21, 2018. The report details a corporate governance action approved by the Board of Directors and Voting Stockholders on August 28, 2018, which became effective upon filing with the Delaware Secretary of State on September 21, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure amendments and does not contain financial performance data.
Material Changes
The primary material change reported is the amendment to the Company's Certificate of Incorporation:
- Common Stock: The number of authorized shares of common stock (par value $0.001 per share) was increased from 400,000,000 to 4,000,000,000.
- Preferred Stock: The number of authorized shares of preferred stock remains unchanged at 1,500,005.
- Total Authorized Capital: The total number of shares of all classes and series the Company is authorized to issue is now 4,001,500,005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the amendment to the Articles of Incorporation and the submission of this matter to a vote of security holders via written consent.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment (September 21, 2018).
- Confirm the new total authorized common share count (4,000,000,000).
- Review the filed Exhibit 3.1 (Certificate of Amendment) for specific legal terms.
- Check subsequent filings for any issuance of shares against the newly authorized capital.